Joint Formulary & PAD

Mometasone furoate with olopatadine - Allergic rhinitis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Nasal spray
Associated Icons :
Restrictions / Comments :
Important
Reserved for use where monotherapy is inadequate. Not 1st line.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Mometasone furoate with olopatadine
Indication :
Allergic rhinitis
Group Name :
Keywords :
Hay fever, hayfever, antihistamines, nasal sprays, allergy, seasonal allergic rhinitis, pollen allergy, intranasal corticosteroids, INCS
Brand Names Include :
Ryaltris
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Committee Recommendations (1)

The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.

To be used  as a 3rd line alternative when monotherapy is inadequate.